The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyImproving the efficacy of chemoradiation with targeted agentsMASTL(Greatwall) regulates DNA damage responses by coordinating mitotic entry after checkpoint recovery and APC/C activationCombination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Chk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth in human colorectal cancer.Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy responseInferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer.Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition.A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cellsThe Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagyTargeting homologous recombination-mediated DNA repair in cancer.Sphingolipids in the DNA damage response.Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.Cell Cycle Regulation and Melanoma.A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells.Triptolide potentiates lung cancer cells to cisplatin-induced apoptosis by selectively inhibiting the NER activity.NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations.CHK1 and RAD51 activation after DNA damage is regulated via urokinase receptor/TLR4 signaling.Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer CellsCell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitorCancer therapeutics revisited; novel drugs targeting cell signalling pathways, genome wide association studies and other trials and tribulations.Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.ATR/CHK1 inhibitors and cancer therapy.A role for caspase-2 in sphingosine kinase 1 proteolysis in response to doxorubicin in breast cancer cells - implications for the CHK1-suppressed pathway.BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer.Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer.Molecular Cell Biology of Apoptosis and Necroptosis in Cancer.
P2860
Q26745686-E9167950-255B-4CC7-BED0-A82CB8F48FBCQ26850193-DEADD789-11A0-491B-989F-150F4CE087EDQ27336474-C79BA14D-0BFB-4228-AE93-6E52BA12192AQ33798999-756F897E-BBD8-425A-8341-22BCB3D26C61Q33983255-3968901D-3DB6-4422-9FF1-2223CAC275A9Q34028486-4D6968C1-2C54-47DC-B3CF-A8C5380D7065Q34055827-A915B66D-8AB0-4B3A-A469-D2610B60B895Q35073758-2265C8B5-4F7B-4F03-BDAF-8EC2933D0090Q35287823-132FEF6A-CF44-4337-AE5B-12AA35E9B166Q35678658-842CAF49-24B9-49E7-9531-BC20170B0FFFQ36111892-D548D49C-E502-4FE6-9CDC-40E90A9FAFDDQ36214686-E2210FB5-ED5C-4A55-B51F-828D990AA4CDQ36545701-EC1360E5-8925-4CEF-B890-7DE7BFBE4D85Q36546455-357678C2-B58D-4DE2-A516-564735FB57DFQ36738836-0F658C98-492F-4B2A-8ABA-B259E3033496Q36771796-63745E89-0AAC-4D82-84D7-5991E0DF8791Q36838392-97F9EAEA-7FA6-4DBB-9E9F-B687D01689BEQ37641736-F20F93E6-27E4-4B99-B0CF-11B988E539FCQ37744731-E4F0A466-37B7-4A75-97ED-70A550D6C118Q38184667-F51A349A-8907-43EF-AF82-27141A420694Q38272799-135217C8-9256-41CB-968F-AD95B5E6FD5DQ38660811-FDCA5BBC-3C25-4206-B3FA-BBEE5EE82E8CQ38695896-21384CB6-9AC6-423C-BCF9-B448B2B6E3B0Q38756843-75E909F5-48D7-4A5C-BDBC-6ED2A0864095Q38815527-D2886F02-C1CB-4918-AC51-F1A7E67AF179Q38838357-C050045A-D336-4AEC-B653-DAA88A64C60BQ38919423-09F88B21-22D7-4BC8-938D-ADE660C83C4AQ41192352-A23912E4-5C38-4ED7-9008-187E48F1A730Q41342397-47D80D39-26C8-4D22-BD3C-FDE0066A805DQ41432461-69BE1F2A-E91E-4A3D-B6DA-71F597BD9AA9Q41470356-00852E5D-F0C8-4FE3-AC99-8B4ACD51C43CQ41838038-D3036246-C72D-49E2-B2E2-F6DE9F9AE960Q42091213-107E869C-526E-4B28-AF0E-398679740214Q43973311-99071063-710C-40FD-862A-03D104629304Q47622968-9948D2BA-1D09-4714-9E1B-FA4FCF4AFFF3Q47658768-FF97D47E-227C-458F-9124-54B599436F11Q47660928-7F69ED6B-D192-4D03-B707-39D4EE367B33Q48269744-227F0233-E4D8-419C-AFEE-541ED101D197Q49547342-51CF5F73-D171-4A8C-AE3F-58071AC93CCBQ50221065-6D461C95-4C93-4B33-B17C-B9E9D125EA25
P2860
The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The cancer therapeutic potenti ...... mpact on clinical trial design
@ast
The cancer therapeutic potenti ...... mpact on clinical trial design
@en
The cancer therapeutic potenti ...... mpact on clinical trial design
@nl
type
label
The cancer therapeutic potenti ...... mpact on clinical trial design
@ast
The cancer therapeutic potenti ...... mpact on clinical trial design
@en
The cancer therapeutic potenti ...... mpact on clinical trial design
@nl
prefLabel
The cancer therapeutic potenti ...... mpact on clinical trial design
@ast
The cancer therapeutic potenti ...... mpact on clinical trial design
@en
The cancer therapeutic potenti ...... mpact on clinical trial design
@nl
P2860
P3181
P356
P1476
The cancer therapeutic potenti ...... mpact on clinical trial design
@en
P2093
Alan Eastman
Ruth Thompson
P2860
P304
P3181
P356
10.1111/BCP.12139
P407
P577
2013-09-01T00:00:00Z